Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Life Sci ; 226: 68-76, 2019 Jun 01.
Article in English | MEDLINE | ID: mdl-30928406

ABSTRACT

AIMS: Rheumatoid arthritis is usually accompanied by various comorbidities especially on the psychological side such as depression. This study aimed at revealing the potential curative effects of venlafaxine (VFX), a serotonin/norepinephrine reuptake inhibitor (SNRI), on experimentally-induced arthritis in rats. METHODS: Arthritis was induced by injecting complete Freund's adjuvant (CFA, 0.1 ml, s.c.). One day thereafter, VFX (50 mg/kg, p.o.) was given for 21 days. Methotrexate was used as a standard disease modifying anti-rheumatic drug. KEY FINDINGS: CFA injection caused prominent arthritis evident by the increase in the hind paw and ankle diameter accompanied by elevating tumor necrosis factor-alpha, interleukin-6, interleukin-17 and matrix metalloproteinase-3 levels, effects that were diminished by VFX. Moreover, VFX down regulated gene expressions of receptor activator of nuclear factor kappa-B (NF-кB) ligand and signal transducer and activator of transcription-3 beside hampering immunohistochemical expression of vascular endothelial growth factor and NF-кB. This SNRI also improved the oxidant status of the hind limb as compared to the arthritic group. Nonetheless, MTX was better in amendment of arthritis authenticated by its effect on some inflammatory and oxidative stress biomarkers. SIGNIFICANCE: This study provides a novel therapeutic use of VFX as a considerable anti-arthritic drug and offers an incentive to expand its use in RA.


Subject(s)
Arthritis, Experimental/drug therapy , Venlafaxine Hydrochloride/metabolism , Venlafaxine Hydrochloride/pharmacology , Animals , Antirheumatic Agents , Arthritis, Experimental/metabolism , Arthritis, Rheumatoid , Biomarkers , Disease Models, Animal , Freund's Adjuvant/pharmacology , Interleukin-17/metabolism , Interleukin-6 , Male , Matrix Metalloproteinase 3 , Methotrexate/pharmacology , NF-kappa B/drug effects , Oxidative Stress , RANK Ligand/drug effects , RANK Ligand/metabolism , Rats , Rats, Sprague-Dawley , STAT3 Transcription Factor/drug effects , STAT3 Transcription Factor/metabolism , Signal Transduction/drug effects , Tumor Necrosis Factor-alpha
2.
Inflammation ; 41(5): 1974-1986, 2018 Oct.
Article in English | MEDLINE | ID: mdl-29982962

ABSTRACT

Articular manifestations are the main hall mark for rheumatoid arthritis; inflammation and oxidative stress are involved in its pathogenesis. This study was designed to figure out the possible therapeutic potential of polydatin on experimentally induced arthritis in rats. Polydatin (POLY) was administered (200 mg/kg, p.o.) for 21 days to complete Freund's adjuvant (CFA; 0.1 ml, s.c.)-induced arthritic rats. Meanwhile, methotrexate (MTX; 0.75 mg/kg, i.p.) was given as a reference standard disease-modifying anti-rheumatic drug (DMARD). Both POLY and MTX significantly attenuated articular damage associated with CFA-induced arthritis. This was manifested by reducing levels of tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6), interleukin-17 (IL-17), and matrix metalloproteinase-3 (MMP-3), paralleled with marked decrease in hind paw and ankle diameters. Moreover, POLY and MTX downregulated gene expressions of receptor activator of nuclear factor kappa-B ligand (RANKL) as well as signal transducer and activator of transcription-3 (STAT3) besides hampering immunohistochemical staining of vascular endothelial growth factor (VEGF) and nuclear factor kappa-B (NF-κB). Furthermore, substantial decline in myeloperoxidase (MPO) activity and malondialdehyde (MDA) level associated with significant rise in reduced glutathione content (GSH) was observed. These findings provide an innovative therapeutic approach of POLY as a natural anti-arthritic drug through modulating IL-6/STAT-3/IL-17/NF-кB cascade. Graphical Abstract ᅟ.


Subject(s)
Arthritis, Experimental/drug therapy , Glucosides/pharmacology , Stilbenes/pharmacology , Animals , Arthritis, Experimental/chemically induced , Freund's Adjuvant , Gene Expression Regulation/drug effects , Glucosides/therapeutic use , Interleukin-17/metabolism , Interleukin-6/metabolism , NF-kappa B/metabolism , Rats , STAT3 Transcription Factor/metabolism , Stilbenes/therapeutic use
3.
J Agric Food Chem ; 65(36): 7966-7981, 2017 Sep 13.
Article in English | MEDLINE | ID: mdl-28813148

ABSTRACT

This study aimed to coat lipid-based nanocarriers with chitosan to encapsulate nutraceuticals, minimize opsonization, and facilitate passive-targeting. Phase one was concerned with standardization according to the World Health Organization. Qualitative analysis using liquid chromatography-high-resolution mass spectrometry (LC-HRMS/MS) investigated the active constituents, especially reported cytotoxic agents. Cinnamaldehyde and rosmarinic acid were selected to be quantified using high-performance liquid chromatography. Phase two was aimed to encapsulate both extracts in solid lipid nanoparticles (core) and chitosan (shell) to gain the advantages of both materials properties. The developed experimental model suggested an optimum formulation with 2% lipid, 2.3% surfactant, and 0.4% chitosan to achieve a particle size of 254.77 nm, polydispersity index of 0.28, zeta potential of +15.26, and entrapment efficiency percentage of 77.3% and 69.1% for cinnamon and oregano, respectively. Phase three was focused on the evaluation of cytotoxic activity unencapsulated/encapsulated cinnamon and oregano extracts with/without 5-fluorouracil on HCT-116 cells. This study confirmed the success of the suggested combination with 5-fluorouracil for treating human colon carcinoma with a low dose leading to decreasing side effects and allowing uninterrupted therapy.


Subject(s)
Antineoplastic Agents/chemistry , Chitosan/chemistry , Cinnamomum zeylanicum/chemistry , Fluorouracil/chemistry , Lipids/chemistry , Origanum/chemistry , Plant Extracts/chemistry , Antineoplastic Agents/pharmacology , Cell Survival/drug effects , Colorectal Neoplasms/drug therapy , Colorectal Neoplasms/physiopathology , Drug Carriers/chemistry , Fluorouracil/pharmacology , HCT116 Cells , Humans , Nanoparticles/chemistry , Plant Extracts/pharmacology
4.
J Biochem Mol Toxicol ; 28(7): 312-9, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24819883

ABSTRACT

This study aimed to assess the protective effect of hesperidin (HES) and rutin (RUT) against cisplatin-induced nephrotoxicity in male rats. Cisplatin (5 mg/kg, intraperitoneal) caused significant increases in serum sodium, blood urea nitrogen, serum creatinine, total sodium and potassium excreted in urine, urine volume, and lipid peroxides measured as the malondialdehyde content of kidney, with significant decreases in serum total protein, creatinine clearance, reduced glutathione content of kidney, and kidney superoxide dismutase activity as compared with the control group. On the other hand, administration of HES (200 mg/kg, per oral [p.o.]) or RUT (30 mg/kg, p.o.) for 14 days with a single cisplatin dose on the tenth day ameliorated the cisplatin-induced nephrotoxicity as indicated by the restoration of kidney function and oxidative stress biomarkers. Furthermore, the test drugs reduced the histopathological changes induced by cisplatin. In conclusion, HES and RUT showed protective effects against cisplatin-induced nephrotoxicity.


Subject(s)
Antioxidants/therapeutic use , Cisplatin/adverse effects , Citrus/chemistry , Hesperidin/therapeutic use , Kidney Diseases/chemically induced , Kidney Diseases/drug therapy , Rutin/therapeutic use , Animals , Antioxidants/pharmacology , Hesperidin/pharmacology , Kidney/drug effects , Kidney/pathology , Kidney/physiopathology , Kidney Diseases/blood , Kidney Diseases/physiopathology , Kidney Function Tests , Male , Organ Size/drug effects , Oxidative Stress/drug effects , Rats, Sprague-Dawley , Rutin/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...